Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial

Cancer immunology research

Volumn 1, Issue 5, 2013, Pages 340-350

  Tsuji, Takemasa ^a   Sabbatini, Paul ^a   Jungbluth, Achim A ^a   Ritter, Erika ^a   Pan, Linda ^a   Ritter, Gerd ^a   Ferran, Luis ^a   Spriggs, David ^a   Salazar, Andres M ^a   Gnjatic, Sacha ^a  

^a Oncovir   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOXYMETHYLCELLULOSE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD40 LIGAND; CTAG1B PROTEIN, HUMAN; EPITOPE; MANNITOL; MEMBRANE PROTEIN; MONTANIDE ISA 51; OLEIC ACID; PEPTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; TUMOR ANTIGEN;

ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARBOXYMETHYLCELLULOSE SODIUM; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; EPITOPES, T-LYMPHOCYTE; HUMANS; MANNITOL; MEMBRANE PROTEINS; OLEIC ACIDS; PEPTIDES; POLY I-C; POLYLYSINE;

EID: 84921305177     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0089     Document Type: Article

References (0)